Improved Natural Killer cell activity and retained anti-tumor CD8( ) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
E Muraro, E Comaro, R Talamini, E Turchet, G Miolo, S Scalone, L Militello, D Lombardi, S Spazzapan, T Perin, S Massarut, D Crivellari, Riccardo Dolcetti, D Martorelli
Journal of Translational Medicine | BMC | Published : 2015
BACKGROUND: Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together with the immune-modulating activities of NC drugs suggest a potential contribution of host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring in locally advanced BC patients undergoing NC to identify immunological correlates of pCR induction. METHODS: The immune profile of 40 HER2-positive and 38 HER2-negative BC patients was characterized at diagnosis and throughout NC (Paclitaxel and Trastuzumab, or Docetaxel ..View full abstract
Awarded by Associazione Italiana per la Ricerca sul Cancro
This study was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (contract 14287 to RD). Elena Muraro was supported by a Fondazione Umberto Veronesi Fellowship. The authors thank the patients and the other investigators participating in the study, and Miss S. Colussi for editing the manuscript.